Dysmenorrhea and Premenstrual Syndrome

  • Christine L. Cook
Part of the Clinical Perspective in Obstetrics and Gynecology book series (CPOG)


Painful menstruation or dysmenorrhea is the most common medical disorder occurring in adolescent females. The recurrent crampy lower abdominal pain experienced by many young women is usually accompanied by one or more nonspecific complaints. These include nausea, vomiting, diarrhea, headaches, and muscle cramps. Although considerable attention has been focused on the psychosocial aspects of this process, work during the last two decades has shifted the emphasis toward physiologic changes. The important role of prostaglandins (PG) in the pathophysiology of this condition and the value of the prostaglandin synthetase inhibitors (PGSI) in the treatment of dysmenorrhea have been elucidated.


Luteal Phase Naproxen Sodium Mefenamic Acid Premenstrual Syndrome Premenstrual Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klein HR, Litt IF: Epidemiology of adolescent dysmenorrhea. Pediatrics 68: 661–4, 1981PubMedGoogle Scholar
  2. 2.
    Andersch B, Milsom I: An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 144: 655–60, 1982PubMedGoogle Scholar
  3. 3.
    Royal College of General Practitioners: Oral Contraception and Health. An Interim Report from the Oral Contraceptive Study of the RCGP. New York, Pitman Medical, 1974, p 63Google Scholar
  4. 4.
    Trobough GE: Pelvic pain the IUD. J Reprod Med 20: 167–74, 1978PubMedGoogle Scholar
  5. 5.
    Csapo AI, Pulkkinen MO, Henzl MR: The effect of naproxen sodium on the intrauterine pressure and menstrual pain of dysmenorrheic subjects. Prostaglandin 13: 193–9, 1977CrossRefGoogle Scholar
  6. 6.
    Akerlund M: Pathophysiology of dysmenorrhea. Acta Obstet Gynecol Scand (Suppl) 87: 27–32, 1979CrossRefGoogle Scholar
  7. 7.
    Pickles VR: A plain muscle stimulant in the menstruum. Nature 180: 1198–9, 1957PubMedCrossRefGoogle Scholar
  8. 8.
    Pickles VR, Hall WJ, Best FA, et al: Prostaglandins in endometrium and menstrual fluid from normal and dysmenorrheic subjects. Br J Obstet Gynaecol 72: 185–92, 1965CrossRefGoogle Scholar
  9. 9.
    Eglinton G, Raphael RA, Smith GN, Hall WJ, Pickles VR: Isolation and identification of two smooth muscle stimulants from menstrual fluid. Nature 200: 960–95, 1963PubMedCrossRefGoogle Scholar
  10. 10.
    Pickles VR: Prostaglandins in the human endometrium. Int J Fertil 12: 335–8, 1967PubMedGoogle Scholar
  11. 11.
    Lündstrum V, Green K: Endogenous levels of prostaglandin F2a and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130: 640–6, 1978Google Scholar
  12. 12.
    Rees MCP, Ancerson ABM, Demers LM, et al: Prostaglandin levels in menstrual fluid in dysmenorrhea and menorrhagia. International Symposium on Dysmenorrhea and Premenstrual Syndrome, Kiawah Island, South Carolina, September, 1983Google Scholar
  13. 13.
    Tsang BK, Ooi TC: Prostaglandin secretion by human endometrium in vitro. Am J Obstet Gynecol 142: 626–33, 1982PubMedGoogle Scholar
  14. 14.
    Auletta FJ, Agins H, Scommegna A: Prostaglandin F2ot medication of the inhibitory effect of estrogen on the corpus luteum of the rhesus monkey. Endocrinology 103: 1183–9, 1978PubMedCrossRefGoogle Scholar
  15. 15.
    Ylikorkala O, Dawood MY: New concepts in dysmenorrhea. Am J Obstet Gynecol 130:833– 47, 1978Google Scholar
  16. 16.
    Owen PR: Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 148: 96–103, 1984PubMedGoogle Scholar
  17. 17.
    Rosenwaks Z, Jones GS, Henzl MR, et al: Naproxen sodium, aspirin, and placebo in primary dysmenorrhea. Reduction of pain and blood levels of prostaglandin F2a metabolite. Am J Obstet Gynecol 140: 592–8, 1981PubMedGoogle Scholar
  18. 18.
    Klein JR, Litt IF, Rosenberg A, Udall L: The effect of aspirin on dysmenorrhea in adolescents. J Pediatr 98: 987–90, 1981PubMedCrossRefGoogle Scholar
  19. 19.
    Black E: The treatment of dysmenorrhea with phenylbutazone. Can Med Assoc J 79: 752–3, 1958PubMedGoogle Scholar
  20. 20.
    Boehm FH, Sarratt H: Indomethacin for the treatment of dysmenorrhea. A preliminary report. J Reprod Med 15: 84–6, 1975Google Scholar
  21. 21.
    Dingfelder JR: Primary dysmenorrhea treatment with prostaglandin inhibitors: a review. Am J Obstet Gynecol 140: 874–9, 1981PubMedGoogle Scholar
  22. 22.
    Budoff PW: Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 241: 2713–16, 1979PubMedCrossRefGoogle Scholar
  23. 23.
    Kapadia L, Elder MG: Flufenamic acid in treatment of primary spasmodic dysmenorrhea. Lancet 1: 348–50, 1978PubMedCrossRefGoogle Scholar
  24. 24.
    Chan WY, Fuchs F, Powell AM: Effects of naproxen sodium on menstrual prostaglan¬dins and primary dysmenorrhea. Obstet Gynecol 61: 285–91, 1983PubMedGoogle Scholar
  25. 25.
    Chan WY, Dawood MY: Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 8: 1443–7, 1980PubMedGoogle Scholar
  26. 26.
    Dawood MY: Dysmenorrhea. Clin Obstet Gynecol 26: 719–27, 1983CrossRefGoogle Scholar
  27. 27.
    Ulmsten U, Andersson K-E, Forman A: Treatment of primary dysmenorrhea by calcium antagonists. International Symposium on Dysmenorrhea and Premenstrual Syndrome, Kiawah Island, South Carolina, September 1983Google Scholar
  28. 28.
    Davies AJ, Anderson ABM, Burnbull AC: Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstet Gynecol 57: 74–87, 1981PubMedGoogle Scholar
  29. 29.
    Fraser IS, Pearse FC, Shearman RP, et al: Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 58: 543–51, 1981PubMedGoogle Scholar
  30. 30.
    Frank RT: The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 26: 1052–7, 1931Google Scholar
  31. 31.
    Greene R, Dalton K: The premenstrual syndrome. Br Med J 1: 1007–15, 1953PubMedCrossRefGoogle Scholar
  32. 32.
    Hargrove JT, Abraham GE: The incidence of premenstrual tension in a gynecologic clinic. J Reprod Med 27: 721–4, 1982PubMedGoogle Scholar
  33. 33.
    Labrum AH: Hypothalamic, pineal and pitui¬tary factors in the premenstrual syndrome. J Reprod Med 28: 438–45, 1983PubMedGoogle Scholar
  34. 34.
    Ruble DN: Premenstrual symptoms: a reinter- pretation. Science 197: 291–2, 1977PubMedCrossRefGoogle Scholar
  35. 35.
    Abraham EG: Premenstrual tension. Curr Prob Obstet Gynecol 3: 1–39, 1980Google Scholar
  36. 36.
    Tonks CM: Premenstrual tension. Br J Psychiatry Spec Publ 9: 399–408, 1975Google Scholar
  37. 37.
    Backstrom T, Mattsson B: Correlation of symptoms in premenstrual tension to oestrogen and progesterone concentrations in blood plasma. Neuropsychobiology 1: 80–6, 1975PubMedCrossRefGoogle Scholar
  38. 38.
    Morton JH: Premenstrual tension. Am J Obstet Gynecol 60: 343–52, 1950PubMedGoogle Scholar
  39. 39.
    Anderson AN, Larsen JF, Steeshrup OR, et al: Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial. Br J Obstet Gynaecol 84: 370–4, 1977CrossRefGoogle Scholar
  40. 40.
    Gray LA: The use of progesterone in nervous tension states. South Med J 34: 1004–6, 1941CrossRefGoogle Scholar
  41. 41.
    Andersch B, Hahn L, Wendestam C, et al: Treatment of premenstrual tension syndrome with bromocriptine. Acta Endocrinol (Suppl 88 ) 216: 165–74, 1978Google Scholar
  42. 42.
    Kutner SJ, Brown WL: Types of oral contraceptives, depression, and premenstrual symp¬toms. J Nerv Ment Dis 155: 153–62, 1972PubMedCrossRefGoogle Scholar
  43. 43.
    Greenhill JP, Freed SC: The electrolyte therapy of premenstrual distress. JAMA 117: 504–6, 1941Google Scholar
  44. 44.
    PreedyJRK, Aitken EH: The effect of estrogen on water and electrolyte metabolism. I. The normal: J Clin Invest 35: 423–9, 1956Google Scholar
  45. 45.
    Schwartz UD, Abraham GE: Corticosterone and aldosterone levels during the menstrual cycle. Obstet Gynecol 45: 339 - 42, 1975PubMedGoogle Scholar
  46. 46.
    Golub LJ, Menduke H, Conley SS: Weight changes in college women during the menstrual cycle. Am J Obstet Gynecol 91: 89–94, 1965PubMedGoogle Scholar
  47. 47.
    Bruce J, Russell GF: Premenstrual tension: a study of weight changes and balances of water, sodium, and potassium. Lancet 2: 267–71, 1962PubMedCrossRefGoogle Scholar
  48. 48.
    Reid RL, Yen SSC: Premenstrual syndrome. Am J Obstet Gynecol 139: 85–104, 1981PubMedGoogle Scholar
  49. 49.
    Budoff P: Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. N Engl J Med 307: 714–19, 1982PubMedCrossRefGoogle Scholar
  50. 50.
    Wood C, Jakubowixz D: The treatment of premenstrual symptoms with mefenamic acid. Br J Obstet Gynaecol 87: 627–30, 1980iPubMedCrossRefGoogle Scholar
  51. 51.
    Jakubowicz DL, Godard E, Dewhurst J: The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br J Obstet Gynaecol 91: 78–84, 1984PubMedCrossRefGoogle Scholar
  52. 52.
    Nicoll CS: Physiological actions of prolactin. In Greep RO, As two od EB (eds): Handbook of Physiology, Vol 4. Washington, DC, American Physiological Society, 1974Google Scholar
  53. 53.
    Baumann E, Marynick SP, Winters SJ, et al: The effect of osmotic stimuli on prolactin secretion and renal water excretion in normal men and in chronic hyperprolactinemia. J Clin Endocrinol Metab 44: 199–202, 1977PubMedCrossRefGoogle Scholar
  54. 54.
    Halbreich U, Assael M, Ben-David M, et al: Serum prolactin in women with premenstrual syndrome. Lancet 2: 654–5, 1976PubMedCrossRefGoogle Scholar
  55. 55.
    Mabray CR, Burditt ML, Martin TL, et al: Treatment of common allergy management procedures. Obstet Gynecol 59: 560–4, 1982PubMedGoogle Scholar
  56. 56.
    Morton JH, Additon H, Addison RG, et al: A clinical study of premenstrual tension. Am J Obstet Gynecol 65: 1182–91, 1953PubMedGoogle Scholar
  57. 57.
    Reid RL, Yen SSC: The premenstrual syndrome. Clin Obstet Gynecol 26: 710–18, 1983PubMedCrossRefGoogle Scholar
  58. 58.
    Quigley ME, Yen SSC: The role of endogenous opiates of LH secretion during the menstrual cycle. J Clin Endocrinol Metab 51: 179–81, 1980PubMedCrossRefGoogle Scholar
  59. 59.
    Peck SD: Can increased beta-endorphins explain the etiology of premenstrual syndrome? J Am Osteopath Assoc 82: 192–7, 1982PubMedGoogle Scholar
  60. 60.
    Dalton K: The Premenstrual Syndrome and Oral Progesterone Therapy. London, Heine- mann, 1977, p 83Google Scholar
  61. 61.
    Sampson GA: Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br J Psychiatry 135: 209–15, 1979PubMedCrossRefGoogle Scholar
  62. 62.
    Chakmakjian ZH: A critical assessment of therapy for the premenstrual tension syndrome. J Reprod Med 28: 532–8, 1983PubMedGoogle Scholar
  63. 63.
    O’Brien PM: The premenstrual syndrome: a review of the present status of therapy. Drugs 24: 140–51, 1982PubMedCrossRefGoogle Scholar
  64. 64.
    Mattson B, van Schoultz B: A comparison between lithium, placebo, and a diuretic in premenstrual tension. Acta Psychiatr Scand 255 (Suppl): 75–84, 1974CrossRefGoogle Scholar
  65. 65.
    Reeves BD, Garvin JE, McElin TW: Premenstrual tension: symptoms and weight changes related to potassium therapy. Am J Obstet Gynecol 109: 1036–41, 1971PubMedGoogle Scholar
  66. 66.
    Stokes J, Mendels J: Pyridoxine and premenstrual tension. Lancet 1: 1177–8, 1972PubMedCrossRefGoogle Scholar
  67. 67.
    Abraham GE, Hargrove JT: Effect of vitamin B6 on premenstrual symptomatology in women with premenstrual tension syndrome—a double-blind crossover study. Infertility 3: 155–65, 1980Google Scholar
  68. 68.
    Mattes JA, Martin D: Pyridoxine in premen¬strual depression. Hum Nutr Appl Nutr 35A: 131–3, 1982Google Scholar
  69. 69.
    Andersch B: Bromocriptine and premenstrual symptoms: a survey of double-blind trials. Obstet Gynecol SUIT 38: 643–6, 1983CrossRefGoogle Scholar
  70. 70.
    Andersen AN, Larsen JF, Steenstrup OR, et al: Effect of bromocriptine on the premenstrual syndromes. A double-blind clinical trial. Br J Obstet Gynaecol 84: 270–4, 1977Google Scholar
  71. 71.
    Day JB: Clinical trials in the premenstrual syndrome. Curr Med Res Opin 6 (S5): 40–5, 1979CrossRefGoogle Scholar
  72. 72.
    Mansel RE, WisbeyJR, Hughes LE: The use of danazol in the treatment of painful breast disease: preliminary results. Postgrad Med J 55 (S5): 61–5, 1979PubMedGoogle Scholar
  73. 73.
    Horrobin DF, Brush MG: Premenstrual syndrome (PMS) and essential fatty acid (EFA) metabolism. International Symposium on Dysmenorrhea and Premenstrual Syndrome, Kiawah Island, South Carolina, September 1983Google Scholar

Copyright information

© Springer-Verlag New York,Inc 1985

Authors and Affiliations

  • Christine L. Cook

There are no affiliations available

Personalised recommendations